Business
Inspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State
RA'ANANA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced the deployment and initiation of a structured commercial evaluation of its U.S. Food and Drug Administration (“FDA”)-cleared INSPIRA™ ART100 system (the “ART100”) at a new and additional leading U.S. academic medical center. The partnering institution is a promin
About this update from Qtrex Quantum Ltd.
[{"type":"image","alt":"Inspira Technologies","displaySize":"","headline":null,"caption":"Inspira Technologies","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/f3cd7fe01a01b6d2fcb4b07615d7a878"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_Fe6OoV8FaU0yBPMg3F6WQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f3cd7fe01a01b6d2fcb4b07615d7a878","width":300,"height":71}},"lazy":false},{"type":"text","content":"RA'ANANA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced the deployment and initiation of a structured commercial evaluation of its U.S. Food and Drug Administration (“FDA”)-cleared INSPIRA™ ART100 system (the “ART100”) at a new and additional leading U.S. academic medical center.","length":471,"tagName":"p"},{"type":"text","content":"The partnering institution is a prominent health system serving a large patient population, and is ranked among New York State’s top 10 hospitals in Newsweek’s World’s Best Hospitals 2025 ranking.","length":196,"tagName":"p"},{"type":"text","content":"This deployment expands Inspira Technologies’ presence within the Tier-1 U.S. hospital market. The ART100 system has been integrated into the center’s clinical workflow to support a structured evaluation designed to define clinical protocols and potential broader institutional adoption. This activity builds upon the Company’s FDA clearance and ongoing commercial activity at other leading U.S. healthcare facilities.","length":418,"tagName":"p"},{"type":"text","content":"Mike Hershkovitz, Global VP Sales at Inspira Technologies, commented: “This deployment represents a continued execution of our U.S. commercial strategy. Following our recent interaction with other leading healthcare providers, entering another leading institution in New York State demonstrates that the ART100 meets the operational and clinical demands of top-tier U.S. healthcare providers. Our focus remains on converting these high-profile evaluations into a sustainable commercial pipeline and further expanding our footprint across key U.S. markets.”","length":556,"tagName":"p"},{...